Brickell Biotech Stock Operating Margin
| BBI Stock | USD 0.90 0.01 1.10% |
Brickell Biotech fundamentals help investors to digest information that contributes to Brickell Biotech's financial success or failures. It also enables traders to predict the movement of Brickell Stock. The fundamental analysis module provides a way to measure Brickell Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Brickell Biotech stock.
| Last Reported | Projected for Next Year | ||
| Operating Profit Margin | (112.17) | (106.56) |
Brickell | Operating Margin |
Brickell Biotech Company Operating Margin Analysis
Brickell Biotech's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Brickell Biotech Operating Margin | (6.58) % |
Most of Brickell Biotech's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Brickell Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Brickell Operating Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Brickell Biotech is extremely important. It helps to project a fair market value of Brickell Stock properly, considering its historical fundamentals such as Operating Margin. Since Brickell Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Brickell Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Brickell Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Brickell Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Brickell Biotech has an Operating Margin of -6.5753%. This is 81.26% lower than that of the Biotechnology sector and 94.13% lower than that of the Health Care industry. The operating margin for all United States stocks is 19.33% higher than that of the company.
Brickell Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Brickell Biotech's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Brickell Biotech could also be used in its relative valuation, which is a method of valuing Brickell Biotech by comparing valuation metrics of similar companies.Brickell Biotech is currently under evaluation in operating margin category among related companies.
Brickell Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of Brickell Biotech from analyzing Brickell Biotech's financial statements. These drivers represent accounts that assess Brickell Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Brickell Biotech's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 191.9K | 325.2K | 425.2K | 408.5K | 367.7K | 386.1K | |
| Enterprise Value | (24.6M) | (6.9M) | (29.2M) | (26.4M) | (30.4M) | (31.9M) |
Brickell Fundamentals
| Return On Equity | -1.57 | ||||
| Return On Asset | -0.8 | ||||
| Operating Margin | (6.58) % | ||||
| Current Valuation | (8.35 M) | ||||
| Shares Outstanding | 2.87 M | ||||
| Shares Owned By Insiders | 1.20 % | ||||
| Shares Owned By Institutions | 13.07 % | ||||
| Number Of Shares Shorted | 189.59 K | ||||
| Price To Earning | (35.16) X | ||||
| Price To Book | 0.41 X | ||||
| Price To Sales | 1.45 X | ||||
| Revenue | 404 K | ||||
| Gross Profit | (27.83 M) | ||||
| EBITDA | (39.38 M) | ||||
| Net Income | (39.47 M) | ||||
| Cash And Equivalents | 17.29 M | ||||
| Cash Per Share | 6.52 X | ||||
| Total Debt | 69 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 4.36 X | ||||
| Book Value Per Share | 5.81 X | ||||
| Cash Flow From Operations | (36.15 M) | ||||
| Short Ratio | 0.62 X | ||||
| Earnings Per Share | (0.42) X | ||||
| Target Price | 17.83 | ||||
| Number Of Employees | 16 | ||||
| Beta | 0.0796 | ||||
| Market Capitalization | 6.75 M | ||||
| Total Asset | 29.72 M | ||||
| Retained Earnings | (145.37 M) | ||||
| Working Capital | 24.79 M | ||||
| Current Asset | 52.66 M | ||||
| Current Liabilities | 5.61 M | ||||
| Net Asset | 29.72 M |
About Brickell Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Brickell Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brickell Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brickell Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Brickell Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Brickell Biotech's short interest history, or implied volatility extrapolated from Brickell Biotech options trading.
Pair Trading with Brickell Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brickell Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brickell Biotech will appreciate offsetting losses from the drop in the long position's value.Moving against Brickell Stock
| 0.82 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.81 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.68 | XFOR | X4 Pharmaceuticals Earnings Call This Week | PairCorr |
| 0.66 | NRSNW | NeuroSense Therapeutics | PairCorr |
| 0.61 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Brickell Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brickell Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brickell Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brickell Biotech to buy it.
The correlation of Brickell Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brickell Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brickell Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brickell Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Brickell Biotech Piotroski F Score and Brickell Biotech Altman Z Score analysis. For more detail on how to invest in Brickell Stock please use our How to Invest in Brickell Biotech guide.Note that the Brickell Biotech information on this page should be used as a complementary analysis to other Brickell Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Brickell Stock analysis
When running Brickell Biotech's price analysis, check to measure Brickell Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brickell Biotech is operating at the current time. Most of Brickell Biotech's value examination focuses on studying past and present price action to predict the probability of Brickell Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brickell Biotech's price. Additionally, you may evaluate how the addition of Brickell Biotech to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |
Is Brickell Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brickell Biotech. If investors know Brickell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brickell Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.42) | Revenue Per Share 1.94 | Quarterly Revenue Growth 27.576 | Return On Assets (0.80) | Return On Equity (1.57) |
The market value of Brickell Biotech is measured differently than its book value, which is the value of Brickell that is recorded on the company's balance sheet. Investors also form their own opinion of Brickell Biotech's value that differs from its market value or its book value, called intrinsic value, which is Brickell Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brickell Biotech's market value can be influenced by many factors that don't directly affect Brickell Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brickell Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Brickell Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brickell Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.